Stockholm Biotech Hansa Files FDA Application for Rare Disease Trial

Hansa Biopharma has submitted a new drug application to the US FDA. This filing marks significant clinical progress for Stockholm's biotech sector.

The company submitted an Investigational New Drug application for HNSA-5487. This drug is a novel IgG-cleaving enzyme. The filing aims to start Phase 2a clinical studies in Guillain-Barré syndrome.

Hansa Biopharma is currently listed on Nasdaq Stockholm. This update provides valuable industry insight for local biotech workers in Greater Stockholm.